Alison Clough, Executive Director – Commercial UK, responds to 'Regulation of the pharmaceutical industry: promoting health or protecting wealth?' published in the journal of the Royal Society of Medicine (RSM).
Regulation of the pharmaceutical industry: promoting health or protecting wealth? on RSM's website.
"Under the five year voluntary Pharmaceutical Price Regulation Scheme (PPRS), the pharmaceutical industry has recognised the financial challenges facing the NHS and we will help keep NHS expenditure on branded medicines in the scheme flat for two years and within agreed controlled growth levels for a further three years.
The industry will underwrite any further expenditure by the NHS within agreed boundaries. The 2015/16 Mandate for NHS England includes a central payment of £796 million in respect of the PPRS payment. Industry expects the total payment to reach £4 billion over the length of the scheme.
Regarding the Cancer Drugs Fund, the ABPI has consistently said that it is a sticking plaster. What is needed is urgent transformation of NICE which will ensure that the right patients get the right medicines at the right time whatever their condition.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: